{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Control+Form+5&page=5",
    "query": {
      "intervention": "Placebo Control Form 5",
      "page": 5
    },
    "page_size": 10
  },
  "pagination": {
    "page": 5,
    "page_size": 10,
    "total_count": 215,
    "total_pages": 22,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Control+Form+5&page=6&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Control+Form+5&page=4&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-31T02:47:07.828Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00403767",
      "title": "An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Atrial Fibrillation",
        "Stroke",
        "Embolism"
      ],
      "interventions": [
        {
          "name": "Rivaroxaban",
          "type": "DRUG"
        },
        {
          "name": "Warfarin",
          "type": "DRUG"
        },
        {
          "name": "Matching placebo for Rivaroxaban arm (Warfarin placebo)",
          "type": "DRUG"
        },
        {
          "name": "Matching placebo for Warfarin arm (Rivaroxaban placebo)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14269,
      "start_date": "2006-12",
      "completion_date": "2010-09",
      "has_results": true,
      "last_update_posted_date": "2014-04-29",
      "last_synced_at": "2026-10-31T02:47:07.828Z",
      "location_count": 295,
      "location_summary": "Birmingham, Alabama • Dothan, Alabama • Geneva, Alabama + 292 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Geneva",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Pell City",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00403767"
    },
    {
      "nct_id": "NCT02315703",
      "title": "Safety, Tolerability, and Immunogenicity Study of Homologous Ad26 Mosaic Vector Vaccine Regimens or Heterologous Ad26 Mosaic and MVA Mosaic Vector Vaccine Regimens With Glycoprotein 140 (gp140) for Human Immunodeficiency Virus (HIV) Prevention",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Ad26.Mos.HIV",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MVA-Mosaic",
          "type": "BIOLOGICAL"
        },
        {
          "name": "gp140 DP Low-dose",
          "type": "BIOLOGICAL"
        },
        {
          "name": "gp140 DP High-dose",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Janssen Vaccines & Prevention B.V.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 393,
      "start_date": "2014-12-22",
      "completion_date": "2022-03-28",
      "has_results": true,
      "last_update_posted_date": "2025-02-04",
      "last_synced_at": "2026-10-31T02:47:07.828Z",
      "location_count": 5,
      "location_summary": "Aurora, Colorado • Miami, Florida • Rockville, Maryland + 2 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Rockville",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02315703"
    },
    {
      "nct_id": "NCT04666610",
      "title": "A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Childhood Absence Epilepsy",
        "Juvenile Absence Epilepsy"
      ],
      "interventions": [
        {
          "name": "Brivaracetam",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "UCB Biopharma SRL",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "2 Years to 25 Years"
      },
      "enrollment_count": 154,
      "start_date": "2021-07-29",
      "completion_date": "2026-07-07",
      "has_results": false,
      "last_update_posted_date": "2026-10-30",
      "last_synced_at": "2026-10-31T02:47:07.828Z",
      "location_count": 10,
      "location_summary": "Birmingham, Alabama • Orange, California • Denver, Colorado + 7 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04666610"
    },
    {
      "nct_id": "NCT01110551",
      "title": "Tetravalent Chimeric Dengue Vaccine Trial",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Dengue"
      ],
      "interventions": [
        {
          "name": "Placebo (SC)",
          "type": "DRUG"
        },
        {
          "name": "Placebo (ID)",
          "type": "DRUG"
        },
        {
          "name": "Modified Live Tetravalent Chimeric Dengue Vaccine (SC)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Modified Live Tetravalent Chimeric Dengue Vaccine (ID)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 72,
      "start_date": "2010-05",
      "completion_date": "2012-12",
      "has_results": false,
      "last_update_posted_date": "2013-02-04",
      "last_synced_at": "2026-10-31T02:47:07.828Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01110551"
    },
    {
      "nct_id": "NCT03885245",
      "title": "Supplementing L-citrulline to Overweight Late Asthma oNset Phenotypes",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Asthma",
        "Obesity"
      ],
      "interventions": [
        {
          "name": "L-ctirulline",
          "type": "DRUG"
        },
        {
          "name": "Matching Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 60,
      "start_date": "2021-10-01",
      "completion_date": "2026-06-30",
      "has_results": false,
      "last_update_posted_date": "2025-06-10",
      "last_synced_at": "2026-10-31T02:47:07.828Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03885245"
    },
    {
      "nct_id": "NCT02467400",
      "title": "Dose Response and Receptor Selectivity of Beta-blocker Effects on Bone Metabolism",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Osteoporosis, Age-Related"
      ],
      "interventions": [
        {
          "name": "Atenolol",
          "type": "DRUG"
        },
        {
          "name": "Nebivolol",
          "type": "DRUG"
        },
        {
          "name": "Propranolol",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "70 Years",
        "sex": "FEMALE",
        "summary": "50 Years to 70 Years · Female only"
      },
      "enrollment_count": 165,
      "start_date": "2015-07-01",
      "completion_date": "2018-04-01",
      "has_results": false,
      "last_update_posted_date": "2019-02-06",
      "last_synced_at": "2026-10-31T02:47:07.828Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02467400"
    },
    {
      "nct_id": "NCT00368251",
      "title": "Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease (ULD) in Adolescents and Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Unverricht-Lundborg Disease"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "BRV 2.5 mg",
          "type": "DRUG"
        },
        {
          "name": "BRV 25 mg",
          "type": "DRUG"
        },
        {
          "name": "BRV 50 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "UCB Pharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 56,
      "start_date": "2006-11",
      "completion_date": "2008-01",
      "has_results": true,
      "last_update_posted_date": "2023-05-31",
      "last_synced_at": "2026-10-31T02:47:07.828Z",
      "location_count": 4,
      "location_summary": "San Francisco, California • Gainesville, Florida • New York, New York + 1 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Charlottesville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00368251"
    },
    {
      "nct_id": "NCT01893554",
      "title": "Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in Infants and Children",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Respiratory Syncytial Virus Infections"
      ],
      "interventions": [
        {
          "name": "RSV ΔNS2 Δ1313 I1314L Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "4 Months",
        "maximum_age": "59 Months",
        "sex": "ALL",
        "summary": "4 Months to 59 Months"
      },
      "enrollment_count": 88,
      "start_date": "2013-06-01",
      "completion_date": "2023-04-26",
      "has_results": false,
      "last_update_posted_date": "2026-05-13",
      "last_synced_at": "2026-10-31T02:47:07.828Z",
      "location_count": 2,
      "location_summary": "Baltimore, Maryland • Laurel, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Laurel",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01893554"
    },
    {
      "nct_id": "NCT07623811",
      "title": "Efficacy and Safety of Acute Topical and Aromatic Essential Oil-Based Products for Cognitive Support",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Cognitive Support System",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "dōTERRA International",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 313,
      "start_date": "2026-06-10",
      "completion_date": "2026-09-23",
      "has_results": false,
      "last_update_posted_date": "2026-10-15",
      "last_synced_at": "2026-10-31T02:47:07.828Z",
      "location_count": 1,
      "location_summary": "Pleasant Grove, Utah",
      "locations": [
        {
          "city": "Pleasant Grove",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07623811"
    },
    {
      "nct_id": "NCT01190839",
      "title": "A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Crohn's Disease"
      ],
      "interventions": [
        {
          "name": "Infliximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Janssen Biotech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 297,
      "start_date": "2010-11",
      "completion_date": "2014-12",
      "has_results": true,
      "last_update_posted_date": "2016-02-04",
      "last_synced_at": "2026-10-31T02:47:07.828Z",
      "location_count": 62,
      "location_summary": "Birmingham, Alabama • La Jolla, California • Orange, California + 59 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Redwood City",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01190839"
    }
  ]
}